ES2098029T5 - Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado. - Google Patents

Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.

Info

Publication number
ES2098029T5
ES2098029T5 ES93906601T ES93906601T ES2098029T5 ES 2098029 T5 ES2098029 T5 ES 2098029T5 ES 93906601 T ES93906601 T ES 93906601T ES 93906601 T ES93906601 T ES 93906601T ES 2098029 T5 ES2098029 T5 ES 2098029T5
Authority
ES
Spain
Prior art keywords
monofosforil
disabled
lipido
vaccines containing
hepatitis vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93906601T
Other languages
English (en)
Other versions
ES2098029T3 (es
Inventor
Nathalie Marie- Garcon-Johnson
Pierre Hauser
Clothilde Thiriart
Pierre Voet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2098029(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of ES2098029T3 publication Critical patent/ES2098029T3/es
Application granted granted Critical
Publication of ES2098029T5 publication Critical patent/ES2098029T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PRESENTA UNA FORMULACION PARA UNA VACUNA PARA EL TRATAMIENTO O PROFILAXIS DE LA HEPATITIS B QUE COMPRENDE EL ANTIGENO DE LA HEPATITIS Y UN PORTADOR ADECUADO TAL COMO ALUMBRE EN COMBINACION CON UN LIPIDO DE MONOFOSFORIL 3-O-DESACILADO. TAMBIEN SE DESCRIBEN VACUNAS DE COMBINACION QUE INCLUYEN LA FORMULACION DE LA VACUNA.
ES93906601T 1992-03-27 1993-03-24 Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado. Expired - Lifetime ES2098029T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine

Publications (2)

Publication Number Publication Date
ES2098029T3 ES2098029T3 (es) 1997-04-16
ES2098029T5 true ES2098029T5 (es) 2002-03-16

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93906601T Expired - Lifetime ES2098029T5 (es) 1992-03-27 1993-03-24 Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.

Country Status (27)

Country Link
EP (1) EP0633784B2 (es)
JP (1) JP3470719B2 (es)
KR (1) KR100270134B1 (es)
CN (1) CN1072963C (es)
AP (1) AP570A (es)
AT (1) ATE146678T1 (es)
AU (4) AU3751693A (es)
CA (1) CA2132833C (es)
CZ (1) CZ283424B6 (es)
DE (1) DE69306940T3 (es)
DK (1) DK0633784T4 (es)
ES (1) ES2098029T5 (es)
FI (1) FI110843B (es)
GR (1) GR3022174T3 (es)
HU (1) HU221253B1 (es)
IL (1) IL105161A (es)
MA (1) MA22842A1 (es)
MY (1) MY111880A (es)
NO (1) NO309458B1 (es)
NZ (1) NZ249868A (es)
RU (1) RU2121849C1 (es)
SA (1) SA93130573B1 (es)
SG (1) SG48375A1 (es)
SI (1) SI9300149B (es)
SK (1) SK280160B6 (es)
UA (1) UA44688C2 (es)
WO (1) WO1993019780A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ATE157882T1 (de) * 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
RU2116086C1 (ru) * 1997-08-19 1998-07-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Способ вакцинации против вирусного гепатита b
WO1999045957A2 (en) * 1998-03-09 1999-09-16 Smithkline Beecham Biologicals S.A. Combined vaccine compositions
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
RU2135209C1 (ru) * 1998-07-17 1999-08-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Фармацевтическая композиция для иммунопрофилактики вирусного гепатита b
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
KR20070058631A (ko) 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
PT1861120T (pt) 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
ES2420829T3 (es) 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
EP1951298A1 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3753574A1 (en) 2006-01-27 2020-12-23 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
HRP20140488T1 (hr) 2006-07-17 2014-07-04 Glaxosmithkline Biologicals S.A. Cjepivo protiv influence
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
ES2536401T3 (es) 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
EP2403507B1 (en) 2009-03-05 2018-02-21 McCloskey, Jenny Colleen Treatment of infection
EP4218799A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US9550811B2 (en) 2010-12-02 2017-01-24 Bionor Immuno As Peptide scaffold design
US9493514B2 (en) 2011-01-06 2016-11-15 Bionor Immuno As Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
DK2707385T3 (da) 2011-05-13 2017-11-20 Glaxosmithkline Biologicals Sa RSV-F-præfusionsantigener
JP6310909B2 (ja) 2012-06-06 2018-04-11 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
HK1254344A1 (zh) 2015-06-26 2019-07-19 Seqirus UK Limited 抗原匹配的流感疫苗
CN118987191A (zh) 2018-11-13 2024-11-22 变异生物技术公司 用于治疗乙型肝炎的免疫原性组合物
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584866D1 (de) * 1984-09-12 1992-01-23 Chiron Corp Hybridpartikel-immunogene.
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
AU3748489A (en) * 1988-06-17 1990-01-12 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0414374T3 (da) * 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
WO1991004262A1 (en) * 1989-09-15 1991-04-04 National Institute Of Health Of Japan New hcv isolates
SU1678373A1 (ru) * 1989-10-18 1991-09-23 Киевский Научно-Исследовательский Институт Эпидемиологии И Инфекционных Болезней Им.Л.В.Громашевского Способ иммунокоррекции при зат жных формах гепатита
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
EP0563091A1 (en) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen

Also Published As

Publication number Publication date
AU1000802A (en) 2002-02-21
DE69306940T3 (de) 2002-09-19
NZ249868A (en) 1997-03-24
AU6445796A (en) 1996-11-07
HU9402758D0 (en) 1994-12-28
FI944442L (fi) 1994-09-26
CA2132833A1 (en) 1993-10-14
ATE146678T1 (de) 1997-01-15
DE69306940D1 (de) 1997-02-06
FI944442A0 (fi) 1994-09-26
AU3751693A (en) 1993-11-08
NO943571L (no) 1994-11-14
AU767755B2 (en) 2003-11-20
SG48375A1 (en) 1998-04-17
NO309458B1 (no) 2001-02-05
SK280160B6 (sk) 1999-09-10
SA93130573B1 (ar) 2004-08-31
UA44688C2 (uk) 2002-03-15
CZ235594A3 (en) 1995-02-15
DK0633784T3 (da) 1997-01-20
EP0633784A1 (en) 1995-01-18
EP0633784B2 (en) 2001-10-17
KR100270134B1 (ko) 2000-10-16
CN1072963C (zh) 2001-10-17
MY111880A (en) 2001-02-28
FI110843B (fi) 2003-04-15
ES2098029T3 (es) 1997-04-16
HK1003218A1 (en) 1998-10-16
DK0633784T4 (da) 2001-12-31
AP9300502A0 (en) 1993-04-30
AP570A (en) 1996-11-29
RU94042386A (ru) 1996-08-20
HU221253B1 (en) 2002-09-28
GR3022174T3 (en) 1997-03-31
EP0633784B1 (en) 1996-12-27
SK115294A3 (en) 1995-06-07
SI9300149B (sl) 2003-02-28
KR950700757A (ko) 1995-02-20
MA22842A1 (fr) 1993-10-01
SI9300149A (en) 1993-12-31
DE69306940T2 (de) 1997-06-26
IL105161A0 (en) 1993-07-08
HUT69931A (en) 1995-09-28
NO943571D0 (no) 1994-09-26
CZ283424B6 (cs) 1998-04-15
JPH07505372A (ja) 1995-06-15
AU3397499A (en) 1999-08-19
CN1085805A (zh) 1994-04-27
RU2121849C1 (ru) 1998-11-20
CA2132833C (en) 2007-03-06
JP3470719B2 (ja) 2003-11-25
WO1993019780A1 (en) 1993-10-14
IL105161A (en) 1998-08-16

Similar Documents

Publication Publication Date Title
ES2098029T5 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
ES2090364T3 (es) Material de implante de vascularizacion cercana.
ES2103956T3 (es) Configuracion de sujecion para articulos absorbentes.
MX9303773A (es) Composicion de vacuna que comprende un antigeno y/o una composicion antigenica de qs21 y monofosforil-lipido a 3-des-o-acilado y proceso para su elaboracion.
ES2129461T3 (es) Proteina hibrida entre cs de plasmodium y hbsag.
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
ES2159517T3 (es) Grapas esteriles e instrumento para su colocacion.
MX9306499A (es) Composiciones farmaceuticas que contienen una anfetamina.
ES2081102T5 (es) Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.
ES2179105T3 (es) Adyuvantes proteinicos.
DK393187A (da) Laegemiddel med antitumorvirkning
MX9202546A (es) Dimeros de rapamicina y composicion farmaceutica que los contiene.
MY113428A (en) Hepatitis b vaccine
CO5011037A1 (es) Metodo para mejorar la condicion de la piel de un usuario en el area cubierta por un articulo absorbente
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
ES2053897T3 (es) Un metodo para estabilizar factores de coagulacion de la sangre.
MX9300550A (es) Estructura de fibra absorbente.
UY24654A1 (es) Composición de vacuna contra la malaria
ES2046852T3 (es) Un procedimiento para preparar un champu.
ES2051695T3 (es) Tratamiento de la trombosis que contiene un fibrinolitico y un analogo de carbaciclina.
ES2089923T3 (es) Composicion de vacuna subunitaria recombinante viva y procedimiento de preparacion.
NL300189I1 (nl) Acellulair vaccin.
ES2042740T3 (es) Dispositivo de informacion.
ES2138005T3 (es) Emplasto analgesico anti-inflamatorio que contiene piroxicam.
ES2063172T3 (es) Sistema terapeutico superficial con una sustancia activa antineoplasica, en especial 5-fluoruracilo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 633784

Country of ref document: ES